Inovio Pharmaceuticals, Inc. Forecast, price target & analysts
Inovio Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Inovio Pharmaceuticals, Inc. Classifications & Recommendation:
Inovio Pharmaceuticals, Inc. Price Target
| Target Price | $7.65 |
| Price | $1.37 |
| Potential |
458.39%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Inovio Pharmaceuticals, Inc. 2026 .
The average Inovio Pharmaceuticals, Inc. target price is $7.65.
This is
458.39%
register free of charge
$13.65
896.35%
register free of charge
$2.02
47.45%
register free of charge
|
|
| A rating was issued by 9 analysts: 6 Analysts recommend Inovio Pharmaceuticals, Inc. to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Inovio Pharmaceuticals, Inc. stock has an average upside potential 2026 of
458.39%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.22 | 0.08 |
| 73.49% | 63.73% | |
| Net Margin | -48,750.00% | -94,181.56% |
| 199.46% | 93.19% |
7 Analysts have issued a sales forecast Inovio Pharmaceuticals, Inc. 2025 . The average Inovio Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
7 Inovio Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Inovio Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.95 | -2.05 |
| 35.14% | 48.10% | |
| P/E | negative | |
| EV/Sales | negative |
7 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast for earnings per share. The average Inovio Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Inovio Pharmaceuticals, Inc....
Current Inovio Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Piper Sandler |
Locked
➜
Locked
|
Locked | Jul 09 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | May 14 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | May 14 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 19 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Mar 19 2025 |
| Citizens Capital Markets |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 13 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Jul 09 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
May 14 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
May 14 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 19 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Mar 19 2025 |
|
Locked
Citizens Capital Markets:
Locked
➜
Locked
|
Mar 14 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 13 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
